


Discovery could explain failed clinical trials for Alzheimer's, and provide a solution

September 19 2018



PET scan of a human brain with Alzheimer's disease. Credit: public domain

Researchers at King's College London have discovered a vicious feedback loop underlying brain degeneration in Alzheimer's disease which may explain why so many drug trials have failed. The study also



identifies a clinically approved drug which breaks the vicious cycle and protects against memory-loss in animal models of Alzheimer's.

Overproduction of the protein beta-amyloid is strongly linked to development of Alzheimer's disease but many drugs targeting betaamyloid have failed in clinical trials. Beta-amyloid attacks and destroys synapses—the connections between nerve cells in the <u>brain</u>—resulting in memory problems, dementia and ultimately death.

In the new study, published in *Translational Psychiatry*, researchers found that when beta-amyloid destroys a synapse, the <u>nerve cells</u> make more beta-amyloid driving yet more synapses to be destroyed.

"We show that a vicious positive feedback loop exists in which betaamyloid drives its own production," says senior author Dr. Richard Killick from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN). "We think that once this feedback loop gets out of control it is too late for drugs which target beta-amyloid to be effective, and this could explain why so many Alzheimer's <u>drug trials</u> have failed."

"Our work uncovers the intimate link between synapse loss and betaamyloid in the earliest stages of Alzheimer's disease," says lead author Dr. Christina Elliott from the IoPPN. "This is a major step forward in our understanding of the disease and highlights the importance of early therapeutic intervention."

The researchers also found that a protein called Dkk1, which potently stimulates production of beta-amyloid, is central to the positive feedback loop. <u>Previous research by Dr. Killick</u> and colleagues identified Dkk1 as a central player in Alzheimer's, and while Dkk1 is barely detectable in the brains of young adults its production increases as we age.

Instead of targeting beta-amyloid itself, the researchers believe targeting



Dkk1 could be a better way to halt the progress of Alzheimer's disease by disrupting the <u>vicious cycle</u> of beta-amyloid production and synapse loss.

"Importantly, our work has shown that we may already be in a position to block the <u>feedback loop</u> with a drug called fasudil which is already used in Japan and China for stroke." says Dr. Killick. "We have convincingly shown that fasudil can protect synapses and memory in animal models of Alzheimer's, and at the same time reduces the amount of beta-amyloid in the brain."

The researchers found that in mice engineered to develop large deposits of beta-amyloid in their brains as they age, just two weeks of treatment with fasudil dramatically reduced the beta-amyloid deposits.

Researchers at King's College London are now seeking funding to run a trial in early stage sufferers of Alzheimer's to determine if fasudil improves brain health and prevents cognitive decline.

Professor Dag Aarsland from the IoPPN said "As well as being a safe drug, fasudil appears to enter the brain in sufficient quantity to potentially be an effective treatment against beta-amyloid. We now need to move this forward to a clinical trial in people with early stage Alzheimer's disease as soon as possible."

More information: Christina Elliott et al, A role for APP in Wnt signalling links synapse loss with β -amyloid production, *Translational Psychiatry* (2018). DOI: 10.1038/s41398-018-0231-6

Provided by King's College London



Citation: Discovery could explain failed clinical trials for Alzheimer's, and provide a solution (2018, September 19) retrieved 19 April 2024 from https://medicalxpress.com/news/2018-09-discovery-clinical-trials-alzheimer-solution.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.